Sutro Biopharma logo
Sutro Biopharma
STRO | NASDAQ
Chart Builder DCF Calculator
$9.32
-$0.50 (-5.09%)
At close: Nov 16, 2026, 4:00 PM ET
$9.32
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Sutro Biopharma Company Profile

Company profile explained

Company Profile

Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.

Key Executives

Name Position
Jane Chung Chief Executive Officer & Director
Gregory K. Chow Chief Financial Officer
David Pauling Chief Administrative Officer & General Counsel
Devendra Luhar Senior Vice President of Technical Operations
Hans-Peter Gerber Chief Scientific Officer
James R. Swartz Founder
Jonathan Fawcett DPHIL MBBS VP & Head of Clinical Development
Kari E. Leetch Senior VP and Head of People & Culture
Lucas Donigian Senior Vice President of Business Development
Regina Cheng Vice President & Controller

Latest SEC Filings

Date Type Title
Sep 22, 2026 4 Filing
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 12, 2026 10-Q Quarterly Report
Aug 12, 2026 8-K Current Report
Jul 30, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Jun 09, 2026 4 Filing
Jun 09, 2026 4 Filing
Jun 09, 2026 4 Filing
Jun 09, 2026 4 Filing
View All SEC Filings ➞
Sutro Biopharma
Sutro Biopharma logo
Country United States
IPO Date Sep 27, 2018
Industry Biotechnology
Sector Healthcare
Employees 128
CEO Jane Chung

Contact Details

111 Oyster Point Boulevard South San Francisco, California 94080 United States

Stock Details

Ticker Symbol STRO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001382101
CUSIP Number 869367201
ISIN Number US8693672011
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.